SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Madrigal Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (86)4/4/2019 11:40:53 AM
From: DewDiligence_on_SI  Read Replies (1) | Respond to of 138
 
HbA1c >=9% suggests a compliance problem, so it's probably a good idea to exclude such people.



To: Miljenko Zuanic who wrote (86)4/30/2019 2:27:16 PM
From: tuck  Read Replies (2) | Respond to of 138
 
Interesting "tweetorial" from a nephrologist, concerning NASH trial outcomes metrics, sampling error, etc. Still working on the implications for MDGL. I'll accept help. My first thought is it suggests there would be high risk/reward to doing longer trials or extensions.

NASH tweetorial

Cheers, Tuck


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News